Journey Medical (NASDAQ:DERM – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01), FiscalAI reports. Journey Medical had a negative net margin of 14.82% and a negative return on equity of 37.36%. The company had revenue of $15.96 million for the quarter, compared to the consensus estimate of $15.47 million.
Here are the key takeaways from Journey Medical’s conference call:
- EMROSI was the clear growth driver, with Q1 revenue of $6.3 million and prescriptions rising to about 30,000, while the company said uptake improved sequentially despite typical early-year seasonality.
- Journey Medical said it now has pricing agreements with the three largest PBM-linked GPOs, giving EMROSI access to more than 169 million of 192 million commercial lives and supporting broader formulary adoption.
- The company highlighted improving product economics, with revenue per prescription rising sequentially and the refill-to-new prescription ratio moving to about 1.5:1, which management views as evidence of growing patient satisfaction and payer progress.
- First-quarter financials showed 21% revenue growth to $16 million, a reduced GAAP net loss of $2.2 million, and positive adjusted EBITDA of $600,000, underscoring improving operating leverage.
- Management plans to add up to five sales representatives and potentially launch up to two new niche dermatology products later this year, while also pursuing additional publications and payer discussions for EMROSI.
Journey Medical Stock Performance
DERM stock traded down $0.11 during midday trading on Friday, reaching $6.24. The stock had a trading volume of 223,462 shares, compared to its average volume of 202,167. The stock has a market cap of $170.43 million, a PE ratio of -16.93 and a beta of 1.03. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.53 and a current ratio of 1.79. The firm has a fifty day simple moving average of $5.84 and a two-hundred day simple moving average of $7.30. Journey Medical has a 52-week low of $4.31 and a 52-week high of $9.56.
Hedge Funds Weigh In On Journey Medical
Analyst Ratings Changes
A number of brokerages have issued reports on DERM. Weiss Ratings reiterated a “sell (d-)” rating on shares of Journey Medical in a research note on Monday, April 20th. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Journey Medical in a report on Thursday, March 26th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $13.00.
Check Out Our Latest Research Report on Journey Medical
About Journey Medical
Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.
The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.
Featured Articles
- Five stocks we like better than Journey Medical
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Journey Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Journey Medical and related companies with MarketBeat.com's FREE daily email newsletter.
